Rhodiola Crenulata as an Adjunctive Therapy in COPD

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that add-on Rhodiola L extract capsule to the regimen of patients with moderate-to-severe COPD (1) may provide a potential of systemic effects of anti-inflammation and anti-oxidation for these patients, and these effects (2) may reflect in the improvement of patients' physiological measurements, quality of life and exercise tolerance.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chung Shan Medical University

Criteria

Inclusion Criteria:

1. moderate-to-severe COPD patients

2. aged 40-80 years,

3. abstaining from cigarette smoking or maintaining a stable dose of cigarette consumption,

4. no acute exacerbation of COPD,

5. clinically being stable for one month and longer,

6. not undergoing exercise training program.

Exclusion Criteria:

1. uncontrolled diabetes mellitus by plasma fasting sugar >200 mg/dl,

2. uremia or CKD stage 5,

3. chronic heart failureby NYFC III,

4. cerebrovascular disease,

5. uncontrolled anemia by Hb < 10 mg/dl,

6. active malignant diseases,

7. other hospitalized acute illness,

8. systemic prednisolone > 10 mg per day.